Mardia Samyoung Posts ₹222.60 Lakhs Net Profit in FY26, Files Newspaper Publication

3 min read     Updated on 14 May 2026, 12:34 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Mardia Samyoung Capillary Tubes Company Limited reported a net profit of ₹222.60 lakhs for the year ended March 31, 2026, on total income of ₹7387.12 lakhs, compared to total income of ₹276.32 lakhs in the prior year. The Board approved the results on May 12, 2026, and the company subsequently filed a newspaper publication of its audited financial results with BSE Limited on May 14, 2026, under Regulation 47 of the SEBI (LODR) Regulations, 2015. Auditors S K Bhavsar & Co. issued an unmodified opinion but flagged the absence of trade receivable/payable confirmations and non-appointment of an internal auditor as matters of emphasis.

powered bylight_fuzz_icon
40151911

*this image is generated using AI for illustrative purposes only.

Mardia Samyoung Capillary Tubes Company Limited has reported its audited financial results for the financial year ended March 31, 2026, with the Board of Directors approving the financial statements during a meeting held on May 12, 2026. The company posted a net profit of ₹222.60 lakhs for the full year, marking a return to profitability compared to the prior year. Subsequently, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted a newspaper publication of its audited financial results to BSE Limited on May 14, 2026. The submission was signed by Managing Director Dhaval Dharmendrabhai Joshi (DIN: 10778731).

Financial Performance

For the year ended March 31, 2026, the company recorded a total income of ₹7387.12 lakhs, a substantial increase compared to the previous year's total income of ₹276.32 lakhs. Revenue from operations for the current financial year stood at ₹7387.12 lakhs, while other income was nil. In the previous year, revenue from operations was zero, with total income derived solely from other income of ₹276.32 lakhs.

The company's total expenses amounted to ₹7038.45 lakhs for the year, up from ₹156.37 lakhs in the previous year. The profit before tax for the period was ₹348.67 lakhs. After accounting for tax expenses of ₹126.07 lakhs, the company achieved a net profit of ₹222.60 lakhs for the year ended March 31, 2026. The table below summarises the key annual financial metrics:

Particulars: FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Revenue from Operations: 7387.12 0.00
Total Income: 7387.12 276.32
Total Expenses: 7038.45 156.37
Profit Before Tax: 348.67 119.95
Net Profit: 222.60 119.95
Basic EPS (₹): 0.33 1.72

Quarterly Results

In the quarter ended March 31, 2026, the company reported a net profit of ₹114.72 lakhs on revenue from operations of ₹6111.74 lakhs. This compares to a net loss of ₹5.39 lakhs in the corresponding quarter of the previous year, where revenue from operations was nil. For the quarter ended December 31, 2025, the company had reported a net profit of ₹129.06 lakhs.

Key Financial Metrics

The basic earnings per share (EPS) for the year ended March 31, 2026, was reported at ₹0.33, compared to ₹1.72 in the previous year. The paid-up equity share capital as of March 31, 2026, stood at ₹6774.64 lakhs, a significant increase from ₹696.14 lakhs in the previous year. This increase was primarily due to the conversion of warrants into equity shares during the period.

Regulatory Compliance

In compliance with Regulation 47 of the SEBI (LODR) Regulations, 2015, the company submitted a copy of the newspaper publication of its audited financial results for the period ended March 31, 2026, to BSE Limited on May 14, 2026. The detailed format of the financial results was also filed with the stock exchange under Regulation 33 of the SEBI (LODR) Regulations, 2015, and is available on the BSE website ( www.bseindia.com ) as well as the company's website ( https://mardiasygltd.com/stock-exchange-compliances/ ).

Parameter: Details
CIN: L20132MH1992PLC069104
Registered Office: A-108, 1st Floor, Chikwadi, Western Express Highway, Andheri East, Mumbai - 400099
Corporate Office: Shop-511 Pratik Mall, Near City Pulse Theatre, Kudasan, Gandhi Nagar, Gandhinagar, Gujarat - 382421
Regulation 47 Submission Date: May 14, 2026
Managing Director: Dhaval Dharmendrabhai Joshi (DIN: 10778731)

Auditor's Report

The statutory auditors, S K Bhavsar & Co., issued an unmodified opinion on the audited standalone financial results. However, the report included an emphasis of matter regarding the absence of balance confirmation letters and reconciliation statements for certain trade receivables and payables. Additionally, the auditors noted that the company had not appointed an internal auditor for the entire financial year 2025-26, constituting a non-compliance with the Companies Act, 2013.

Will Mardia Samyoung Capillary Tubes appoint an internal auditor for FY2026-27 to address the Companies Act non-compliance flagged by auditors, and what corrective measures are planned for trade receivable reconciliation gaps?

Given the massive equity dilution from warrant conversions that drove paid-up capital from ₹696 lakhs to ₹6,774 lakhs, how might this impact future EPS growth and shareholder value if revenue momentum slows?

With revenue from operations surging from zero to ₹7,387 lakhs in a single year, what is the sustainability of this growth trajectory and which product segments or customer contracts are driving this demand?

like15
dislike

Mardia Samyoung Capillary Tubes Reports No Deviation in Preferential Issue Fund Utilisation for Quarter Ended March 31, 2026

2 min read     Updated on 12 May 2026, 11:53 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Mardia Samyoung Capillary Tubes Company Limited filed statements of deviation and variation under SEBI Regulation 32(1) for the quarter ended March 31, 2026, covering nine preferential issue tranches raised between February 4, 2026 and February 16, 2026. The amounts raised across tranches ranged from Rs. 82.49 Lakhs to Rs. 1,976.90 Lakhs, all designated for working capital requirements. The company confirmed no deviation or variation in fund utilisation across all tranches. The filings were certified by S K Bhavsar & Co., Chartered Accountants, and signed by Managing Director Dhaval Dharmendrabhai Joshi.

powered bylight_fuzz_icon
40155807

*this image is generated using AI for illustrative purposes only.

Mardia Samyoung Capillary Tubes Company Limited submitted statements of deviation and variation to the Bombay Stock Exchange on May 12, 2026, pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filings pertain to the quarter ended March 31, 2026, and cover eight separate preferential issue tranches executed between February 4, 2026 and February 16, 2026. In each instance, the company confirmed that no deviation or variation occurred in the utilisation of funds raised.

Overview of Preferential Issue Tranches

The company raised funds across eight tranches through preferential issues, all directed towards meeting working capital requirements. The filings were signed by Managing Director Dhaval Dharmendrabhai Joshi (DIN: 10778731) and certified by S K Bhavsar & Co., Chartered Accountants (FRN: 145880W), with the reports dated May 12, 2026, from Mumbai. No monitoring agency was appointed for any of the tranches.

The following table summarises the key details of each preferential issue tranche as reported:

Tranche: Date of Raising Funds Amount Raised Deviation/Variation
Tranche 1: 04-02-2026 Rs. 394.875 Lakhs No
Tranche 2: 05-02-2026 Rs. 1259.54 Lakhs No
Tranche 3: 06-02-2026 Rs. 792.45 Lakhs No
Tranche 4: 09-02-2026 Rs. 790.76 Lakhs No
Tranche 5: 10-02-2026 Rs. 1585.57 Lakhs No
Tranche 6: 11-02-2026 Rs. 1976.90 Lakhs No
Tranche 7: 12-02-2026 Rs. 82.49 Lakhs No
Tranche 8: 13-02-2026 Rs. 393.35 Lakhs No
Tranche 9: 16-02-2026 Rs. 1325.38 Lakhs No

Fund Utilisation and Compliance

For each of the preferential issue tranches, the original stated object was to meet working capital requirements. Across all tranches, the company reported no modification to the original object, no change in allocation, and no deviation in the amount of funds utilised as against what was originally disclosed. The fields for modified object, modified allocation, funds utilised, and deviation/variation amount were all marked as not applicable, consistent with a declaration of full compliance.

The Audit Committee comments, auditor comments, and shareholder approval fields were similarly marked as not applicable for all tranches, in line with the absence of any reported deviation or variation.

Regulatory Filing Details

The statements were filed in accordance with the following regulatory framework:

  • Regulation: Regulation 32(1) of SEBI (LODR) Regulations, 2015
  • Report Period: Quarter ended March 31, 2026
  • Filing Date: May 12, 2026
  • Mode of Fund Raising: Preferential Issue
  • Monitoring Agency: Not appointed
  • Certifying Auditor: S K Bhavsar & Co., Chartered Accountants, FRN: 145880W
  • Signatory: Dhaval Dharmendrabhai Joshi, Managing Director, DIN: 10778731

The filings were submitted to the Listing Department of the Bombay Stock Exchange Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai 400001.

How will the deployment of approximately Rs. 8,600 Lakhs in working capital across nine tranches impact Mardia Samyoung's revenue growth and operational capacity in the upcoming quarters?

Given the absence of a monitoring agency for such a substantial multi-tranche preferential issue, will SEBI or BSE likely tighten oversight requirements for similar fundraising structures in the future?

Who were the preferential allottees in these nine tranches, and could their significant capital infusion signal a strategic shift in the company's ownership structure or business direction?

like15
dislike

More News on Mardia Samyoun Capillary Tubes Company Limited